IGC Pharma's novel approach to
Alzheimer's Disease
Reach out to learn more about IGC-AD1's Phase 2b trial for agitation in dementia due to Alzheimer's
Latest Press Release
November 14, 2024
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in its Alzheimer’s Pipeline
Alzheimer's disease affects over 55 million individuals worldwide 1
In treating agitation, which affects 40-80% of individuals with Alzheimer’s disease2, IGC-AD1 has shown promising results.
Drag to discover more
Impacting Lives: Our Work Matters
With no known cure for Alzheimer’s disease, our drugs have the potential to change lives.
5th Leading
Cause of death among
Americans aged 65+3
Expected cost of Alzheimer’s and dementia by 2050 (in 2024 dollars) if no treatment or cure is found3
From the CEO's desk:
Vertical integration
Periodic updates and perspectives on various aspects of our business.
Science Spotlight
Welcome to “Science Spotlight” – your exclusive platform for insights into neurological disorders. Dr. Juan Manuel Orjuela and the IGC Pharma scientific team bring you in-depth articles on conditions such as Alzheimer’s disease, offering comprehensive updates on treatment and understanding their impact on individuals and families. Explore the roles of caregivers and dynamics within affected families. Stay informed with our latest article.
- Feature Article
The Endocannabinoid System and the Immune System: Understanding their interplay in health and Disease
Research has shown a complex interaction between the Endocannabinoid System (ECS) and the immune system, emphasizing the ECS's role in regulating immune responses and preventing excessive inflammation that can lead to tissue damage.
By: Saadia Shahnawaz, MD …
Raising the Voice: A Comment on Race and Ethnic Disparities in Alzheimer’s Disease Clinical Research
Alzheimer's Disease clinical research has faced a significant challenge for a long time in achieving diverse racial or ethnic representation in clinical trials. Many of these issues are rooted in deeper structural problems that leave some populations apart from the scope of science. While much work remains to be done to address this subject, there is a growing demand for more representative clinical trial data.
Hypertension, or high blood pressure, significantly impacts public health worldwide. Hypertension is well recognized for its role in cardiovascular disease, revealing implications for cognitive decline and dementia. Increasing clinical evidence for the early detection, management, and prevention of this condition may provide insights into a more comprehensive patient care, a more effective prevention of cognitive decline, and an improvement of overall quality of life.
Both the primary and secondary objectives aim to evaluate the efficacy of IGC-AD1 in reducing agitation as assessed by the CMAI at week 2 and week 6 respectively.
Parkinson's awareness month ____________________________ Parkinson’s disease psychosis is a neuropsychiatric complication that affects more than 20% of patients affected by Parkinson’s. Common symptoms involve visual or auditory hallucinations, distorted perception, and experiences. More challenging symptoms may occur in the form of delusions, which often cause agitation, aggressiveness, and affect the quality of life of the patient and their families.
By: Faith Ashmore Benzinga …
Investors
Latest News
November 6, 2024
IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss Therapies
October 17, 2024
IGC Pharma Announces Patient Enrollment at Toronto’s Baycrest in Phase 2 Trial Investigating IGC-AD1
October 17, 2024
IGC Pharma Wins 2 Awards in Phase 1 of NIA’S AI PREPARE Challenge, Advancing Alzheimer’s Early Prediction Research
Investing in the Future: Building Brighter Lives for Children
At IGC Pharma, we recognize our commitment to patients, caregivers, and their families, including children. Explore our programs dedicated to children.
- World Health Organization, Dementia, Key facts, 15 March 2023.
- Van der Mussele S et al. Agitation-associated behavioral symptoms in MCI and Alzheimer’s dementia. Aging Ment Health 2014;19(3):247–57.
- Alzheimer’s Association. 2024 Alzheimer’s Disease Facts and Figures. Alzheimers Dement 2024;20(5)